Targeted agents, particularly third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), have a high blood-brain barrier (BBB) penetration rate and show significant efficacy in the treatment of patients with EGFRm NSCLC (8, 9). Here, EGFR is linked to non-small cell lung carcinoma.